Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Artavazd Arumov Ph.D
Principal
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Phil DiGiacomo
Principal
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Co-Founder and Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Will McConnell
Principal
Gary Rieschel
Founder and Managing Partner
James Shen
Venture Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Rachel Wang
Venture Partner
James Wang
Venture Partner
Jing Wu
Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Oscar Zhang
Principal
Yafeng Zhou
Associate
Alex Zhou
Partner
Zhiyuan Zhou
Associate
Zhifeng Zhou
Managing Partner
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Phillip DiGiacomo Ph.D
Principal
Past deals in Series B
Eco Polymer
Series B in 2025
Eco Polymer specializes in research and the production of medical catheters and membrane materials.
Stairway Medical
Series B in 2025
Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.
Auron Therapeutics
Series B in 2025
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.
Baoling Bio
Series B in 2025
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.
Xinzeyuan
Series B in 2025
Xinzeyuan Medical is a manufacturer specializing in precision components and consumables for medical endoscopes. The company focuses on producing minimally invasive surgical instruments and various medical consumables, aimed at enhancing the safety and efficiency of surgical treatments for medical professionals. By delivering high-quality products, Xinzeyuan Medical plays a vital role in supporting healthcare providers and improving patient outcomes.
Leyden Labs
Series B in 2025
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
StepStar
Series B in 2024
The goal of Stepstar is to "Ten Times the Possibility of Everyone" through Intelligent Step. Step Star firmly creates its own super model and actively uses important resources like
Soda Health
Series B in 2024
Soda Health is a healthcare technology company founded in 2021 and based in Chicago, Illinois. The company focuses on addressing health inequities by leveraging social determinants of health. It offers a technology platform designed to assist individuals in identifying, accessing, and funding the resources necessary for a healthy life. By providing a system for administering and reimbursing personalized benefits, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, ultimately promoting better health outcomes.
XellSmart
Series B in 2024
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
Tachem
Series B in 2024
Tachem is a biotechnology company that develops, produces, and distributes a range of products derived from the protected amino acid series. These products cater to diverse industries, including medical, healthcare, food, and cosmetics, serving as high-quality chemical raw materials and biotechnical solutions for various applications.
Hope Medicine
Series B in 2024
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.
Longbio Pharma
Series B in 2024
Longbio Pharma is a biotechnology company focused on developing treatments for patients with complement and allergy diseases, particularly in the autoimmune sector. The company aims to provide affordable and high-quality biomedicines to both domestic and international markets. By leveraging its innovative platform, Longbio Pharma seeks to enhance treatment options for healthcare professionals, ultimately improving patient outcomes in the field of allergy and complement-related illnesses.
Shanghai Mufan Power
Series B in 2024
Mufan Power is a high-tech enterprise specializing in turbomachinery, focused on developing zero-carbon hydrogen power generation technologies. The company manufactures hydrogen gas turbines designed for various applications, including distributed energy systems, data centers, rail transit, marine power, vehicle propulsion, and energy storage peak shaving. Mufan Power also offers technical consultation and engineering services related to gas turbines, steam turbines, and other turbomachinery, having contributed to the design and development of significant national heavy equipment in China.
SPEEDIANCE
Series B in 2024
Speediance focuses on the development of smart self-service gym equipment tailored for at-home strength training. The company offers innovative fitness equipment that integrates an online platform, providing users with training guidance and access to various courses related to strength training. This approach allows individuals to connect with a broader workout community, enhancing their home workout experiences and promoting effective exercise routines.
Pelliot
Series B in 2024
Pelliot is an outdoor sports brand that designs and manufactures high-performance clothing for outdoor enthusiasts. The company specializes in innovative design and research & development, offering a range of products including performance, mountain, classic, and training wear. Pelliot's commitment lies in producing professional-grade outdoor sports products, supporting outdoor lovers with reliable equipment.
Outpace Bio
Series B in 2024
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Engitist
Series B in 2024
Engitist is a company based in Suzhou, China, that specializes in the research, manufacture, and sale of semiconductor optical measurement and testing equipment. Founded in 2018, Engitist offers a range of products including microscopic film measurement, optical defect detection, and optical linewidth measurement. The equipment is designed to provide high accuracy and reliability, enabling semiconductor manufacturers to effectively monitor product quality and enhance the sophistication of their semiconductor products. Engitist serves a global clientele, delivering high-quality solutions tailored to the needs of the semiconductor industry.
Alpha Biopharma
Series B in 2024
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.
Novamab
Series B in 2024
Novamab is engaged in the research and development of innovative nanobody pharmaceuticals aimed at improving treatment options in the pharmaceutical industry. With a team experienced in nanobody research, the company has developed multiple specialized platforms, including an inhaled macromolecular drug platform, an albumin nanobody long-acting platform, and a nanobody double-antibody platform. These innovations leverage the unique advantages of nanobodies to create novel drug delivery methods, such as sprays and eye drops, addressing significant challenges in the management of chronic diseases. Novamab's research focuses on critical medical areas, including tumors, autoimmune disorders, and cardiovascular diseases, ultimately enabling healthcare professionals to enhance patient outcomes.
CureGenetics
Series B in 2024
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
Zhipu AI
Series B in 2024
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.
Hope Medicine
Series B in 2024
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.
Ruining Bio
Series B in 2024
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.
DeBank
Series B in 2024
DeBank is a cryptocurrency wallet designed to facilitate access to decentralized finance (DeFi) services, enabling users to manage and track their DeFi investments effectively. The platform supports over 800 DeFi protocols across more than 15 blockchains, including Ethereum and Binance Smart Chain. Users can monitor their asset portfolios, compare interest rates, and analyze risks associated with their investments. DeBank also offers features for token swapping and discovering new investment opportunities through detailed real-time data, allowing users to gain insights into their financial activities and optimize their returns in the DeFi space.
ABUP
Series B in 2023
ABUP specializes in over-the-air (OTA) solutions for the automotive and Internet of Things (IoT) sectors. The company offers a range of products and services, including firmware upgrades, software upgrades, and cloud diagnosis for automobiles, as well as IoT upgrade solutions. By leveraging artificial intelligence and big data, ABUP enables its customers to keep their products current, ensuring users benefit from a tailored experience and ongoing innovation. Their technology supports original equipment manufacturers by providing comprehensive OTA system solutions that enhance product management and upgrades in the rapidly evolving IoT landscape.
Saints & Sages
Series B in 2023
Saints & Sages Medical specializes in the production and sale of minimally invasive surgical medical devices. The company offers a range of energy device products utilized across various medical fields, including hepatobiliary surgery, gynecology, urology, thoracic surgery, thyroid and breast surgery, and gastrointestinal surgery. By closely monitoring clinical needs, Saints & Sages is committed to developing innovative surgical devices that enhance the accuracy and efficiency of procedures. The company is supported by a dedicated research and development team with extensive experience in clinical transformation, allowing it to continually advance its offerings to better serve patients worldwide.
Solo Music
Series B in 2023
Solo Music is an AI-based music education platform that provides online education services for several musical instruments.
Zhipu AI
Series B in 2023
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.
Cornerstone Robotics
Series B in 2023
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
CuroVax
Series B in 2023
CuroVax, established in 2011 and headquartered in Changzhou City, China, specializes in vaccine development and production. It offers a range of vaccines, including a Freeze-Dried rabies vaccine for human use and an Influenza virus split vaccine, along with related logistics services. The company employs a dual approach of independent development and collaborative research, supported by multiple technology platforms such as large-scale mammalian cell culture and antigen purification, vaccine testing, and mRNA vaccine development. CuroVax aims to provide safe and efficient products, contributing to the improvement of global health.
Abdera Therapeutics
Series B in 2023
Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.
1 Yong Cloud
Series B in 2023
1 Yong Cloud is a Beijing-based company founded in 2017 that specializes in developing a tumor diagnosis and treatment standardization platform. This platform is designed to assist physicians in creating personalized diagnosis and treatment plans for patients with tumor diseases. By collecting and translating medical data, 1 Yong Cloud aims to enhance the quality and consistency of medical care while rationalizing treatment expenses. The company's comprehensive data and system services support healthcare professionals in improving the overall effectiveness of tumor diagnosis and treatment.
Allorion Therapeutics
Series B in 2023
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.
Jiangsu Jing Chuang Advanced Electronic Technology focuses on the research and development of equipment for the semiconductor manufacturing sector. The company specializes in high-precision grinding machines and offers a range of products, including automatic laser saws, dicing saws, and wafer cleaning equipment. By providing comprehensive solutions for semiconductor material dicing applications, Jing Chuang Advanced aims to support the growing demands of the semiconductor industry.
Vongi
Series B in 2023
Vongi offers medical solution design, product design and RandD, pilot test transformation, clinical research, registration services, and commercial operations for companies that need digital therapy, real-world research, and digital therapy CDMO and process services. For inquiries, their email address, telephone number, and physical address are available on their website.
OriCell Therapeutics
Series B in 2023
OriCell Therapeutics is a biopharmaceutical company dedicated to developing innovative, effective, and affordable tumor immunotherapy treatments. It focuses on unmet clinical needs, with a pipeline targeting various cancers including liver, myeloma, ovarian, gastric, cervical, and non-small cell lung cancers.
Hochuen Medical
Series B in 2023
Hochuen Medical USA Corp. is a manufacturer of medical devices and consumables, specializing in In Vitro Diagnostics (IVD), wearable medical technology, and microfluidic devices. Established in 2015 by Dr. Robin Liu and Eric Zeng, the company operates as an OEM/ODM manufacturer, providing services that range from product design and development to mass production. Hochuen Medical's product offerings include essential healthcare items such as COVID-19 testing kits, microfluidic biochips, and various medical disposables. The company is recognized for its commitment to quality, holding FDA registration and ISO certifications, and emphasizes research and development to offer innovative solutions for the healthcare sector. With a founding management team that possesses extensive experience in manufacturing and development, Hochuen Medical aims to address the evolving needs of medical professionals and patients through its diverse product portfolio.
Tingsheng Technology
Series B in 2023
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
Yike Polymers
Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Singular Medical
Series B in 2023
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Insyce
Series B in 2023
Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.
Fitlens
Series B in 2022
Fitlens is a company that provides ophthalmic medical treatment. They specialize in the design and manufacture of high-end, complicated optical contact lenses as well as the design and manufacture of high-end intraocular lens optical molds.
Core Medical
Series B in 2022
Core Medical (Beijing) Co., Ltd. is a contract research organization (CRO) founded in 2013 and based in Beijing, China. The company specializes in clinical professional services focused on new technologies and innovative products within the cardiovascular sector. Core Medical offers a range of services, including animal testing, type testing, First-in-Man (FIM) studies, human studies, and statistics and data management for clinical research. By providing these services, Core Medical helps companies in the cardiovascular field evaluate and validate their products, facilitating advancements in medical technology.
Focallure
Series B in 2022
Focallure is a cosmetic company headquartered in Guangzhou, China, specializing in the development and manufacture of beauty products, particularly base makeup and cosmetics. The company leverages big data analysis to enhance its operations by analyzing consumer product preferences and social content trends. This data-driven approach allows Focallure to create innovative products that aim to provide users with a fresh makeup experience.
iMile
Series B in 2022
iMile is a logistics and courier services provider operating across the Middle East, specializing in solutions for the e-commerce sector. The company is notable for being the first courier service to effectively address Cash On Delivery (COD) needs, offering a suite of services that includes cash-on-delivery options with tracking, real-time online shipment tracking, and comprehensive customer support available through various channels. iMile also facilitates international transport and maintains overseas warehouses, ensuring efficient last-mile delivery. Its innovative platform enables clients to manage cross-border deliveries seamlessly, enhancing the overall logistics experience.
Scroll.io
Series B in 2022
Scroll.io provides a native zkEVM scaling solution for Ethereum. The company upholds the Ethereum network's high-security features while offering users nearly instantaneous, inexpensive transactions.
OriginCell
Series B in 2022
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.
Norm Medtech
Series B in 2022
Norm Medtech focuses on developing interventional medical devices. Norm Medtech is headquartered in Zhejiang, China.
Biren Technology
Series B in 2022
Biren Technology is a high-tech startup specializing in the design and development of intelligent processors tailored for GPU and DSA computation architectures. The company focuses on creating integrated software and hardware platforms that support intelligent computing applications, including cloud computing, artificial intelligence training, graphics rendering, and high-performance general-purpose computing. With a dedicated team of industry experts and elite engineers, Biren Technology aims to deliver versatile computing solutions that blend general computing capabilities with specific applications. Its research division is committed to advancing key technologies in intelligent computing systems, emphasizing new architectures and advanced compilation techniques, thereby facilitating technological breakthroughs in various high-tech sectors.
GYENNO Technologies
Series B in 2022
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.
OriCell Therapeutics
Series B in 2022
OriCell Therapeutics is a biopharmaceutical company dedicated to developing innovative, effective, and affordable tumor immunotherapy treatments. It focuses on unmet clinical needs, with a pipeline targeting various cancers including liver, myeloma, ovarian, gastric, cervical, and non-small cell lung cancers.
Chatail
Series B in 2022
Chatail is a company that specializes in live broadcast sales solutions tailored for private domains. It provides a comprehensive platform that allows businesses to effectively leverage live video for sales purposes. Key features of Chatail's offerings include capabilities for cross-store linking and tools for enhancing enterprise collaboration without the need for live broadcasting. The company develops software that assists brands in initiating live video commerce, empowering sales associates and call center representatives to attract customers to physical retail locations while facilitating meaningful interaction and communication.
Qingflow
Series B in 2022
Qingflow is a software-as-a-service platform based in the Minhang District of Shanghai, specializing in business workflow management. The platform allows users to create customized management systems by freely designing and combining various modules. This flexibility enables individuals and organizations to develop personalized business workflows tailored to their specific needs, all without requiring any programming skills. Qingflow's approach empowers users to effectively manage their operations and enhance productivity through a user-friendly interface.
Gaugene
Series B in 2022
Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.
RiboX Therapeutics
Series B in 2022
RiboX Therapeutics is a biotech company that focuses on discovery and development of fully engineered circular RNA therapeutics.
Cubenergy Technology
Series B in 2022
Cubenergy Technology is an energy technology company specializing in energy data operation services and the integration of distributed energy storage systems. The company develops advanced Energy Management Systems that utilize data analysis to optimize the performance of energy storage systems. By focusing on efficient control mechanisms, Cubenergy Technology aims to enhance system efficiency and provide users with effective energy management solutions.
LaNova Medicines
Series B in 2022
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
Boulder Care
Series B in 2022
Boulder Care, Inc. is a telemedicine-based platform focused on treating opioid addiction through a combination of medication and peer support. Founded in 2017 and located in Portland, Oregon, the company provides comprehensive services that include patient support, medication management, and psychosocial services. By leveraging digital health technology, Boulder Care aims to improve access to effective treatment for individuals struggling with opioid use, enhancing the experience for both patients and their care teams. The organization serves a diverse clientele, including patients, providers, and various health organizations, contributing to the advancement of the behavioral health industry.
BUD
Series B in 2022
BUD, founded in 2019 by former Snap engineers Risa Feng and Shawn Lin, is a Singapore-based company that operates a user-generated open metaverse gaming platform. This platform connects millions of virtual worlds created by a community of approximately 9 million creators. Since its global launch in November 2021, BUD has rapidly gained popularity, ranking among the top 10 social apps in over 38 countries, including regions in North America, Southeast Asia, and South America. The platform allows users to easily customize 3D worlds through a simple drag-and-drop interface, enabling the creation and sharing of interactive experiences that range from social hangouts to competitive games. BUD has evolved into a vibrant digital social hub where users can create, play, and interact with 3D content alongside friends.
Point One
Series B in 2022
Point One is a 3D Metaverse user-generated content platform. Using simple no-code tools, users may build personalized 3D interactive content.
Yike Polymers
Series B in 2022
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Ashermed
Series B in 2022
Ashermed is a provider of contract research organization (CRO) services tailored for medical companies. The company emphasizes the integration of advanced technologies, including Internet technology, big data, and artificial intelligence, into its offerings. By doing so, Ashermed aims to help medical companies shorten the drug development cycle, enhance the quality of clinical data, and lower research and development costs. Their services encompass CRO, site management organization (SMO), patient recruitment, and digital platform support, positioning them as a comprehensive partner in the medical research industry.
Onechip Bioelectronics
Series B in 2022
Wanzhong Yixin Biotechnology is a developer of semiconductor integrated circuit biosensor chips and other related devices. The company's biosensor chip products are used in emerging fields such as genetic testing, water quality monitoring, and environmental protection IoT monitoring.
Vistel
Series B in 2022
Vistel is a technology company founded in 2016 by Sun Yuhui and Ding Dayong, specializing in the application of artificial intelligence in the medical field. The firm focuses on developing AI-driven ophthalmic medical imaging technology designed to enhance the diagnosis of eye diseases. By utilizing advanced diagnostic systems that incorporate computer vision processing and image annotation, Vistel aims to provide medical practitioners with innovative tools for the digital analysis and management of patients' eye conditions.
Curie.Bio
Series B in 2022
Curie.Bio, founded in 2022 and based in Boston, Massachusetts, is a venture capital firm that specializes in seed-stage investments. The firm focuses on early-stage therapeutics companies, aiming to support innovative solutions in the life sciences sector. As a Registered Investment Adviser, Curie.Bio is dedicated to fostering growth and development in the biotechnology field by partnering with founders and providing the necessary resources to help advance their ventures.
MeetFuture
Series B in 2022
MeetFuture China is a technology-focused company that specializes in automated transmission systems for the pan-semiconductor industry. Since its establishment in 2016, it has been providing innovative automation solutions to prominent companies in the semiconductor sector. By leveraging control theory, computer science, and advanced information technology, MeetFuture enables industrial detection, control, optimization, dispatch, and management. These capabilities allow clients to significantly reduce operational costs and effectively manage production parameters, contributing to overall industrial upgrading and development through independent and controllable core technologies.
MediLink Therapeutics
Series B in 2022
MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.
HashQuark
Series B in 2022
HashQuark is a provider of staking and blockchain infrastructure services, specializing in the Proof of Stake (PoS) and Delegated Proof of Stake (DPoS) ecosystems. Founded in 2018 and based in Grand Cayman, the company offers a range of services including staking for institutions, individuals, and market professionals, as well as a Staking Cloud that enables token holders to securely store their tokens and earn staking rewards. HashQuark supports all mainstream PoS blockchains and has completed global server deployment, ensuring secure and stable operations for its clients. The company's focus is on providing efficient node management and fostering investment opportunities for both individual and institutional investors within the blockchain space.
Zhipu AI
Series B in 2022
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.
Deep View Technology
Series B in 2022
Deep View Technology specializes in motion capture and the development of augmented reality (AR) and virtual reality (VR) applications. The company focuses on research and development related to three-dimensional computer vision algorithms. Utilizing wearable devices, Deep View Technology's services enable the identification of body part gestures, allowing clients to capture human postures in real time. This innovative approach enhances interactive experiences in virtual environments.
CureGenetics
Series B in 2022
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
Korro Bio
Series B in 2022
Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.
Tungee
Series B in 2021
Tungee, established in 2016, is a provider of intelligent sales solutions for business-to-business enterprises. By utilizing big data and artificial intelligence technologies, including natural language processing and machine learning, Tungee offers a comprehensive platform that facilitates lead mining, business opportunity engagement, customer relationship management, and order analysis. This platform is designed to help enterprises efficiently identify, contact, and manage customers, thereby reducing customer acquisition costs and enhancing overall sales performance. Tungee has positioned itself as a leader in the Chinese intelligent sales sector, serving over 3,000 enterprise clients, including notable companies such as Alibaba and China Mobile. Through its innovative approach, Tungee addresses the challenges faced by businesses in sales forecasting and customer management.
WoXiaoYa
Series B in 2021
WoXiaoYa is a food and beverage brand that makes and sells chidren's nutritional supplement products.
InfStones
Series B in 2021
InfStones, founded in 2018, operates as a prominent blockchain infrastructure provider with offices in three countries across two continents. The company specializes in offering services to large institutional clients worldwide, facilitating the management of thousands of nodes on over 50 public blockchains through its universal platform. Additionally, InfStones has developed a decentralized cloud storage solution that allows institutions to securely establish and host their mainnet. This platform is designed to simplify the process of connecting with blockchain technology, enabling clients to efficiently develop and deploy their applications on various blockchain networks.
DP Technology
Series B in 2021
DP Technology is a global leader in the "AI for Science" research paradigm, where AI learns scientific principles and data, then tackles key challenges in scientific research and industrial R&D. DP's commitment to interdisciplinary research has led to the creation of the DP "Particle Universe", an array of pre-trained large science models designed to bridge foundational research with practical industrial applications. DP's software suite includes the Bohrium® Scientific Research Space, Hermite® Computational Drug Design Platform, RiDYMO® Dynamics Platform, and Piloteye® Battery Design Automation Platform. Together, these platforms form a robust foundation for industrial innovation and an open ecosystem for AI in science, fostering advancements in key areas such as drug discovery, energy, material science, and information technology.
Wholee
Series B in 2021
Wholee is an e-commerce website, dedicated to become customers' reliable lifetime partners.
Cornerstone Robotics
Series B in 2021
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Platelet BioGenesis
Series B in 2021
Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical use. Founded in 2014, the company has developed a microfluidic bioreactor designed to generate functional platelets from human stem cell cultures at a commercial scale. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing a vital resource for patients worldwide. The company is also focused on advancing therapeutics within the fields of biotechnology and drug discovery.
Okeanos Technology
Series B in 2021
Okeanos Technology specializes in the custom synthesis and production of specialized chemical biological reagents and pharmaceutical intermediates tailored for the life sciences sector. The company's primary offerings include modified nucleotides, unnatural amino acids, heterocycles, and fluorescent and labeling reagents. Okeanos supplies these products to leading pharmaceutical companies, earning a strong reputation for quality and reliability. The firm focuses on providing clients with a diverse range of chemical compounds and biochemical reagents, particularly in the realms of sequencing and synthetic biology.
GenLight Medical
Series B in 2021
Genlight is a company based in Hangzhou, China, that specializes in developing advanced treatment solutions for epilepsy and other neurological disorders. The organization focuses on innovative technologies in the field of brain science and neurosurgery, creating laser medical equipment designed to improve patient outcomes. Genlight's offerings include brain-computer control technology, deep brain nerve stimulation with full-cranial implantation, brain computer chips, and a minimally invasive surgery system guided by magnetic resonance. These high-tech solutions aim to provide patients with effective and cutting-edge surgical options for neurological conditions.
Structure Therapeutics
Series B in 2021
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.
Qingflow
Series B in 2021
Qingflow is a software-as-a-service platform based in the Minhang District of Shanghai, specializing in business workflow management. The platform allows users to create customized management systems by freely designing and combining various modules. This flexibility enables individuals and organizations to develop personalized business workflows tailored to their specific needs, all without requiring any programming skills. Qingflow's approach empowers users to effectively manage their operations and enhance productivity through a user-friendly interface.
Sunyur
Series B in 2021
Shangyue Network Technology specializes in providing digital procurement solutions for large and medium-sized enterprises. The company offers an intelligent procurement platform and software as a service (SaaS) applications that enable businesses to create customized online procurement systems. By leveraging these solutions, organizations can digitize and enhance their procurement processes, ultimately improving operational efficiency and reducing costs. Shangyue's focus on developing tailored procurement platforms allows clients to navigate the complexities of modern purchasing in a streamlined and intelligent manner.
Ventyx Biosciences
Series B in 2021
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.
Alamar Biosciences
Series B in 2021
Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.
Rox Motor
Series B in 2021
ROX Motor is a company dedicated to the development of off-road new energy vehicles, focusing on innovations in smart car technologies. The firm specializes in research and development in areas such as new energy power, intelligent cockpit systems, and autonomous driving. By providing advanced solutions in three-electric technology and intelligent driving, ROX Motor aims to enhance product quality within the new energy vehicle industry. The company's commitment to integrating cutting-edge technologies supports its mission to lead in the smart vehicle market.
GYENNO Technologies
Series B in 2021
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.
moodytiger
Series B in 2021
moodytiger is a technical athletic apparel brand for children from age of 4 to 16. Today, kids from more than 100 countries, from United States to Australia, from Singapore to Hong Kong, have worn moodytiger outfits in their wonderful active adventure! Born to redefine kids’ athlectic wear from day one, our products are specially tailored for children with perfect combination of high-tech fabrics and fashion-forward designs, and functionally suited for multiple sports, including tennis, skiing, skating, swimming, outdoor, and everyday active living. As one of the fastest growing and most innovative brands in the category, we thrive to be the new industry benchmark setter with what we do.
Lingyi Zhihui
Series B in 2021
Zuoshouyisheng's AI doctor platform spans 35 medical specialties and can diagnose more than 6,000 diseases, according to the company’s website. Zuoshouyisheng mainly collaborates with customers through a SaaS business model, providing its AI-empowered healthcare system to hospitals, pharmaceutical companies, employers, and insurers.
Berry Oncology
Series B in 2021
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Zion Pharma
Series B in 2021
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Kingsware
Series B in 2021
Kingsware focuses on developing robotic process automation (RPA) software aimed at enhancing operational efficiency for enterprises across various sectors, including finance and supply chain. The company's RPA system automates repetitive tasks and streamlines business operations through programmed robots, allowing organizations to improve productivity and reduce manual workload. Kingsware is dedicated to creating a robust and secure robotic management platform that is user-friendly and adaptable to large-scale, integrated environments. Its solutions are designed to be safe, efficient, and stable, aligning with the demands of complex enterprise operations.
Health Biotech
Series B in 2021
Health Biotech is a research and development firm specializing in precision medicine through the application of mass spectrometry. The company focuses on early diagnosis, treatment, and monitoring of Alzheimer's disease, employing liquid chromatography-mass spectrometry techniques to quantitatively detect specific biomarkers associated with the condition. By offering comprehensive solutions that include tools, equipment, and reagent consumables, Health Biotech aims to provide reliable detection services for patients. Its innovative technology not only aids in identifying risks for Alzheimer's disease but also supports healthcare professionals in enhancing patient outcomes by delaying disease onset and improving cognitive abilities.
Hope Medicine
Series B in 2021
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.
Just Medical
Series B in 2021
Just Medical is a developer and manufacturer of orthopedic medical devices, specializing in artificial implants such as hip and knee joints, as well as internal fixation products and surgical instruments. The company emphasizes research and development in orthopedics, aiming to enhance surgical efficiency and improve the quality of orthopedic treatment. Just Medical is dedicated to providing safe and effective medical products and services, continually refining its product systems to alleviate patient pain and support healthcare professionals in their surgical procedures.
Valgen Medtech
Series B in 2021
Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.
Tasogare
Series B in 2021
Tasogare Coffee is a premium coffee brand based in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, catering to a wide customer base that values high-quality coffee. Tasogare Coffee is committed to delivering exceptional coffee experiences, emphasizing quality in its offerings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.